• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢综合征与肝移植:综述及处理指南

Metabolic syndrome and liver transplantation: a review and guide to management.

机构信息

Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, MN, USA.

出版信息

J Hepatol. 2010 Jul;53(1):199-206. doi: 10.1016/j.jhep.2010.01.040. Epub 2010 Mar 31.

DOI:10.1016/j.jhep.2010.01.040
PMID:20451282
Abstract

Metabolic syndrome is common among liver transplant recipients before and after transplantation. The components of metabolic syndrome are often exacerbated in the post-transplant period by transplant specific factors, such as immunosuppression, and are strong predictors of patient morbidity and mortality. Many aspects of the metabolic syndrome are modifiable. Early recognition, prevention and treatment of post-transplant hypertension, obesity, dyslipidemia and diabetes may impact long-term post-transplant survival. Further study into the prevention and management of these issues in the transplant patient are needed.

摘要

代谢综合征在肝移植受者移植前后均很常见。移植后,代谢综合征的成分常因移植特异性因素(如免疫抑制)而加重,是患者发病率和死亡率的强有力预测因素。代谢综合征的许多方面是可以改变的。早期识别、预防和治疗移植后高血压、肥胖、血脂异常和糖尿病可能会影响移植后的长期生存。需要进一步研究如何预防和管理移植患者的这些问题。

相似文献

1
Metabolic syndrome and liver transplantation: a review and guide to management.代谢综合征与肝移植:综述及处理指南
J Hepatol. 2010 Jul;53(1):199-206. doi: 10.1016/j.jhep.2010.01.040. Epub 2010 Mar 31.
2
Liver transplantation: role of immunosuppression, renal dysfunction and cardiovascular risk factors.肝移植:免疫抑制、肾功能不全及心血管危险因素的作用
Minerva Chir. 2012 Feb;67(1):1-13.
3
Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review.肝移植后心血管风险、动脉粥样硬化和代谢综合征:小型综述。
Expert Rev Gastroenterol Hepatol. 2013 May;7(4):361-4. doi: 10.1586/egh.13.19.
4
Posttransplant metabolic syndrome: an epidemic waiting to happen.移植后代谢综合征:一场等待发生的流行病。
Liver Transpl. 2009 Dec;15(12):1662-70. doi: 10.1002/lt.21952.
5
Metabolic syndrome and liver transplantation.代谢综合征与肝移植。
Panminerva Med. 2009 Dec;51(4):205-13.
6
Obesity, hyperlipidemia, and metabolic syndrome.肥胖症、高脂血症和代谢综合征。
Liver Transpl. 2009 Nov;15 Suppl 2:S83-9. doi: 10.1002/lt.21914.
7
Long-term outcome after liver transplantation.肝移植后的长期预后。
Mt Sinai J Med. 2012 Mar-Apr;79(2):169-89. doi: 10.1002/msj.21302.
8
Metabolic syndrome and liver transplantation.代谢综合征与肝移植
Minerva Gastroenterol Dietol. 2010 Sep;56(3):297-304.
9
Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events.肝移植受者的代谢综合征:患病率及其与主要血管事件的关联。
Liver Transpl. 2007 Aug;13(8):1109-14. doi: 10.1002/lt.21126.
10
Long-term care of the liver transplant recipient.肝移植受者的长期护理
Clin Liver Dis. 2007 May;11(2):397-416. doi: 10.1016/j.cld.2007.04.003.

引用本文的文献

1
Efficacy and Safety of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in the Treatment of Diabetes Mellitus and Obesity in Liver Transplant Recipients: A Systematic Review.GLP-1受体激动剂和SGLT-2抑制剂治疗肝移植受者糖尿病和肥胖症的疗效与安全性:一项系统评价
J Clin Med. 2025 Jun 30;14(13):4619. doi: 10.3390/jcm14134619.
2
MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function.在肝功能异常的肝移植受者中,MAFLD比NAFLD更容易诊断。
ILIVER. 2022 Sep 20;1(3):194-198. doi: 10.1016/j.iliver.2022.09.001. eCollection 2022 Sep.
3
Cardiac Evaluation in Liver Transplant Candidates.
肝移植候选者的心脏评估
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102554. doi: 10.1016/j.jceh.2025.102554. Epub 2025 Mar 27.
4
Menopause and gastrointestinal health and disease.更年期与胃肠道健康及疾病
Nat Rev Gastroenterol Hepatol. 2025 May 23. doi: 10.1038/s41575-025-01075-7.
5
Novel insights and an updated review of metabolic syndrome in immune-mediated organ transplant rejection.免疫介导的器官移植排斥反应中代谢综合征的新见解及最新综述
Front Immunol. 2025 Apr 22;16:1580369. doi: 10.3389/fimmu.2025.1580369. eCollection 2025.
6
Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation.霉酚酸酯单药替代肝移植中钙调神经磷酸酶抑制剂的适应证及长期疗效
Transpl Int. 2025 Feb 21;38:13790. doi: 10.3389/ti.2025.13790. eCollection 2025.
7
Impact of liver graft steatosis on long-term post-transplant hepatic steatosis and fibrosis via magnetic resonance quantification.通过磁共振定量分析肝移植供肝脂肪变性对移植后长期肝脏脂肪变性和纤维化的影响。
Front Med (Lausanne). 2025 Jan 17;11:1502055. doi: 10.3389/fmed.2024.1502055. eCollection 2024.
8
The impact of new onset diabetes on cardiovascular risks in orthotopic liver transplant recipients: findings from the COLT study.新发糖尿病对原位肝移植受者心血管风险的影响:COLT研究结果
Acta Diabetol. 2024 Nov 11. doi: 10.1007/s00592-024-02406-x.
9
The efficacy and safety of Dachaihu decoction in the treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.大柴胡汤治疗非酒精性脂肪性肝病的疗效与安全性:一项系统评价和Meta分析
Front Med (Lausanne). 2024 Jul 2;11:1397900. doi: 10.3389/fmed.2024.1397900. eCollection 2024.
10
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue.肝移植后代谢功能障碍相关脂肪性肝病(MASLD):一个新出现问题的叙述性综述
J Clin Med. 2024 Jun 30;13(13):3871. doi: 10.3390/jcm13133871.